Multiple Sclerosis
Biogen Idec Receives Positive Opinion from the CHMP and Authorisation from Health Canada on AVONEX PEN
Published in Pharma Law Weekly, May 3rd, 2011
2011 MAY 3 -- Biogen Idec (NASDAQ: BIIB) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of AVONEX® PEN™ for patients with relapsing multiple sclerosis (MS) and patients with a single demyelinating event. The CHMP recommendation provides the basis for a European Commission licensing decision, which is expected within 75 days from the opinion. The company also announced an authorisation for AVONEX PEN from Health Canada.
AVONEX PEN is designed to be the first single-use, once-a-week, fully integrated intramuscular autoinjector available for...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
Source: Pharma Law Weekly (2011-05-03)
More Articles from Pharma Law Weekly
- BayBio
BayBio Targets International Markets at Annual Conference - European College of Neuropsychopharmacology
Bertil Fredholm wins the 2011 ECNP Neuropsychopharmacology Award in basic science research - Bowel Diseases
C. difficile increases risk of death 6-fold in patients with inflammatory bowel disease - CareCore National
CareCore National Partners with President's Challenge Program to Promote the Presidential Active Lifestyle Award - More from this issue of Pharma Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
